Pharmaceutical News

RSS

Japanese MHLW approves Sosei’s Seebri inhalation capsules to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.

28 Sep 2012

Teva concludes Asset Transfer Agreement with NeuroSearch

Teva Pharmaceutical Industries Ltd announced today that it has concluded an Asset Transfer Agreement with NeuroSearch A/S of Denmark to purchase all rights, assets and obligations relating to Huntexil (pridopidine / ACR16), a drug candidate being developed for the symptomatic treatment of hand movement, balance and gait disturbances in Huntington disease (HD).

28 Sep 2012

Study explores effects of immunotherapy on malignant gliomas

In what could be a breakthrough in the treatment of deadly brain tumors, a team of researchers from Barrow Neurological Institute and Arizona State University has discovered that the immune system reacts differently to different types of brain tissue, shedding light on why cancerous brain tumors are so difficult to treat.

28 Sep 2012

Cherry intake reduces risk of gout attacks

A new study found that patients with gout who consumed cherries over a two-day period showed a 35% lower risk of gout attacks compared to those who did not eat the fruit.

28 Sep 2012

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA

ARIAD Pharmaceuticals, Inc. today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational BCR-ABL inhibitor, ponatinib, to the U.S. Food and Drug Administration (FDA).

28 Sep 2012

Janssen introduces new online scientific resource for U.S. healthcare professionals

Janssen Scientific Affairs, LLC today announced the launch of JanssenMD, a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. The web-based application is designed for use on desktops, tablets, and smartphones and can be accessed at www.janssenMD.com.

28 Sep 2012

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

The U.S. Food and Drug Administration today approved Stivarga (regorafenib) to treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body (metastatic).

28 Sep 2012

Roundup: Md. Blues chief pans hospital costs shift plan; Pharmacies struggle with new drug controls

Negotiations to avert a breakdown in Maryland's unique system of regulating hospital prices have deteriorated into a stalemate between the state's largest insurer and the Maryland Hospital Association. CareFirst BlueCross BlueShield CEO Chet Burrell, speaking out for the first time about the talks, blames hospitals for their proposal to shift hundreds of millions in costs to CareFirst and other private insurers in an attempt to control rising Medicare spending.

28 Sep 2012

Story describes need for male version of oral contraceptive pills

When will men have their own birth control pill? Scientists have been predicting the debut of a male pill within 5 years for the last 30 years. The factors accounting for that delay - and new optimism that a male pill will emerge within a decade - are the topic of a story in the current edition of Chemical & Engineering News. C&EN is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

27 Sep 2012

Aeterna Zentari expects to file AEZS-130 NDA with FDA for adult growth hormone deficiency

Aeterna Zentaris Inc. today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted.

27 Sep 2012

Study indicates the amounts paid by antipsychotic manufacturers to D.C. Medicaid psychiatrists

The D.C. Department of Health (DOH) has released a study by George Washington University School of Public Health & Health Services (SPHHS) indicating the high levels of marketing by antipsychotic drug manufacturers to Medicaid psychiatrists in the District of Columbia.

27 Sep 2012

Key bacterial protein structures reveal one of the biochemical secrets behind multi-drug tolerance

The structures of key bacterial proteins have revealed one of the biochemical secrets that enables bacteria to outwit antibiotics.

27 Sep 2012

Anxiety, depression and insomnia drugs and risk of driving accident: an interview with Hui-Ju Tsai

Anxiety, depression and insomnia drugs have been commonly used to treat mental and emotional disorders, or improve sleep-related problems.

27 Sep 2012

Eaton highlights potential of Tropine 3 for women with hot flashes

Eaton Scientific Systems, Ltd. a wholly-owned subsidiary of Pristine Solutions, Inc. is pleased to highlight the increasing international potential of Tropine 3 for the non-hormonal treatment for pre-menopausal, peri-menopausal, and post-menopausal women experiencing hot flashes.

27 Sep 2012

Challenges to India's role as global pharmaceutical supplier

"India has had a positive global impact through its supply of vast quantities of low-cost, good-quality generic medicines, which have saved or prolonged millions of lives ... but there are also many factors that may hinder the continuation of the country's role as chief supplier of medicines to developing countries," Martin Khor, executive director of the South Centre in Geneva, writes in an Inter Press Service opinion piece.

27 Sep 2012

Combination of two neuroprotective therapies shows promise against Alzheimer's

The combination of two neuroprotective therapies, voluntary physical exercise, and the daily intake of melatonin has been shown to have a synergistic effect against brain deterioration in rodents with three different mutations of Alzheimer's disease.

27 Sep 2012

Study sheds new light on potential habit-forming properties of tramadol

A study by a team of University of Kentucky researchers has shed new light on the potential habit-forming properties of the popular pain medication tramadol, in research funded by the National Institute on Drug Abuse.

27 Sep 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

Dr. Reddy's introduces generic Singulair oral granules in the U.S.

Dr. Reddy's Laboratories announced today that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair (montelukast sodium) oral granules in the US market on September, 26, 2012, following the approval by the United States Food & Drug Administration (USFDA) of Dr.Reddy's ANDA for Montelukast Sodium Oral Granules.

27 Sep 2012

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

27 Sep 2012

Pharmaceutical News

Japanese MHLW approves Sosei’s Seebri inhalation capsules to treat COPD

Teva concludes Asset Transfer Agreement with NeuroSearch

Study explores effects of immunotherapy on malignant gliomas

Cherry intake reduces risk of gout attacks

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA

Janssen introduces new online scientific resource for U.S. healthcare professionals

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

Roundup: Md. Blues chief pans hospital costs shift plan; Pharmacies struggle with new drug controls

Story describes need for male version of oral contraceptive pills

Aeterna Zentari expects to file AEZS-130 NDA with FDA for adult growth hormone deficiency

Study indicates the amounts paid by antipsychotic manufacturers to D.C. Medicaid psychiatrists

Key bacterial protein structures reveal one of the biochemical secrets behind multi-drug tolerance

Anxiety, depression and insomnia drugs and risk of driving accident: an interview with Hui-Ju Tsai

Eaton highlights potential of Tropine 3 for women with hot flashes

Challenges to India's role as global pharmaceutical supplier

Combination of two neuroprotective therapies shows promise against Alzheimer's

Study sheds new light on potential habit-forming properties of tramadol

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Dr. Reddy's introduces generic Singulair oral granules in the U.S.

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News